Gamma Vaccines was established to solve one of the great challenges in infectious disease - the development of a “universal” cross-protective influenza virus vaccine. Its product - Gamma-Flu® - is a uniquely inactivated whole-virus vaccine that is expected to provide broad-spectrum immunity to all seasonal and pandemic influenza A viruses. In addition, Gamma Vaccines has a pipeline of vaccine opportunities aimed at preventing other globally important respiratory diseases, such as bacterial pneumonia – a common secondary infection that often follows infection with influenza. The company is also seeking opportunities to exploit its technology platform for veterinary applications, including the production of novel avian influenza vaccines for preventing bird flu outbreaks in poultry. The company upholds the principles of Global Health and will seek to ensure that its improved vaccines are available for both developed and developing country markets – with the aim of reducing global morbidity and mortality from infectious diseases.
